Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01499043 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
A Phase 2 study, sponsored by Daiichi Sankyo.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01499043 is a Phase 2 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 6 participants.
The verdict
NCT01499043, a Phase 2 study, was terminated before completion, sponsored by Daiichi Sankyo.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the effects of PLX3397 on male subjects with CRPC. Secondary objectives include evaluating the safety and tolerability of PLX3397 and the anti-tumor effects that PLX3397 has on the the subjects.
Interventions
- DRUG PLX3397
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-05-25 |
| Est. Completion | 2013-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01499043
The ClinicalTrials.gov registry entry for NCT01499043 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PLX3397 is the first listed.
NCT01499043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01499043 about?
NCT01499043 is a clinical study titled "Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)". The main objective of this study is to evaluate the effects of PLX3397 on male subjects with CRPC. Secondary objectives include evaluating the safety and tolerability of PLX3397 and the anti-tumor effects that PLX3397 has on the the subjects.
What is the current status of trial NCT01499043?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2012-05-25. Estimated completion is 2013-03-11.
What interventions are being tested in trial NCT01499043?
The interventions under investigation include: PLX3397 (DRUG).
Who is sponsoring clinical trial NCT01499043?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.